Todays Report: The Axovant Sciences Ltd. (AXON) Short Interest Update

The Axovant Sciences Ltd. (AXON) Short Interest Update

Axovant Sciences Ltd. (NYSE:AXON) was the recipient of a significant decrease in short interest during the month of October. As of October 14th, there was short interest totalling 4,499,037 shares, a decrease of 52.8% from the September 30th total of 9,537,548 shares. Based on an average daily trading volume, of 240,451 shares, the short-interest ratio is currently 18.7 days. Currently, 18.9% of the shares of the company are sold short.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP purchased a new position in Axovant Sciences during the second quarter valued at approximately $128,000. Woodstock Corp purchased a new position in Axovant Sciences during the second quarter valued at approximately $243,000. Bourgeon Capital Management LLC raised its position in Axovant Sciences by 12.1% in the second quarter. Bourgeon Capital Management LLC now owns 23,200 shares of the company’s stock valued at $298,000 after buying an additional 2,500 shares during the period. California State Teachers Retirement System raised its position in Axovant Sciences by 68.6% in the second quarter. California State Teachers Retirement System now owns 51,249 shares of the company’s stock valued at $658,000 after buying an additional 20,859 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Axovant Sciences by 39.3% in the second quarter. Bank of New York Mellon Corp now owns 72,198 shares of the company’s stock valued at $928,000 after buying an additional 20,368 shares during the period. 29.45% of the stock is currently owned by institutional investors.

A number of brokerages recently commented on AXON. Zacks Investment Research lowered Axovant Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 25th. Robert W. Baird reiterated an “outperform” rating and issued a $29.00 target price on shares of Axovant Sciences in a research report on Monday, October 24th. Jefferies Group restated a “buy” rating and issued a $31.00 price objective on shares of Axovant Sciences in a research report on Monday, September 26th. Evercore ISI restated a “buy” rating and issued a $29.00 price objective on shares of Axovant Sciences in a research report on Friday, September 23rd. Finally, Piper Jaffray Cos. set a $32.00 price objective on Axovant Sciences and gave the stock a “buy” rating in a research report on Friday, September 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $26.33.

Axovant Sciences (NYSE:AXON) opened at 12.72 on Monday. The stock’s 50 day moving average price is $14.40 and its 200 day moving average price is $13.79. The firm’s market capitalization is $1.26 billion. Axovant Sciences has a 52 week low of $8.86 and a 52 week high of $21.30.

Axovant Sciences (NYSE:AXON) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.02. On average, equities analysts expect that Axovant Sciences will post ($1.68) EPS for the current year.

Axovant Sciences Company Profile

Related posts

Leave a Comment